BioSpace News Archive

The board of directors of Health Catalyst, Inc., a leading provider of data and analytics technology and services to healthcare organizations, appointed Julie Larson-Green and S. Dawn Smith to its Board, effective January 1, 2020.

Replimune Group, Inc., a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced a proposed public offering of up to 5,000,000 shares of its common stock.

Expects to Report Initial Clinical Data from Phase 1/2 pheNIX PKU Gene Therapy Clinical Trial by Year-End

Conference call to discuss financial and operational results scheduled for Wednesday, November 13 at 8:30 a.m. U.S. Eastern Time

Halozyme Therapeutics, Inc. announced that it intends to offer, subject to market conditions and other factors, $400 million aggregate principal amount of convertible senior notes due 2024.

CVD Equipment Corporation, a leading provider of chemical vapor deposition systems and materials, announced its third quarter 2019 financial results.

Exelixis, Inc. announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the Stifel 2019 Healthcare Conference being held next week in New York.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, announced its financial results for the quarter ended September 30, 2019 and provided a corporate update.

NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced a proposed public offering of 3,200,000 shares of its common stock.

Iterum Therapeutics plc reported financial results for the third quarter ended September 30, 2019 and provided an update on its clinical programs.